Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-25T14:03:30.228Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroleptic Malignant Syndrome

Published online by Cambridge University Press:  29 January 2018

R. J. Abbott  and
L. A. Loizou
R. J. Abbott*
Affiliation:
Pinderfields General Hospital, Wakefield
L. A. Loizou
Affiliation:
Pinderfields General Hospital, Wakefield
*
St. James's University Hospital, Beckelt Street, Leeds 9.
Get access Rights & Permissions [Opens in a new window]

Abstract

The neuroleptic malignant syndrome (NMS) occurs as a hypersensitivity response in certain patients exposed to neuroleptics. It is a relatively rare, but potentially lethal complication, the incidence of which may have been underestimated. Recent interest in NMS has arisen due to the recognition that specific therapy may now be available. This review summarises the clinical features and discusses recent ideas regarding aetiology and treatment.

Type
Papers
Information
The British Journal of Psychiatry , Volume 148 , Issue 1 , January 1986 , pp. 47 - 51
Copyright
Copyright © 1986 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allan, R. C. & White, H. C. (1972) Side effects of long acting phenothiazines. British Medical Journal, i, 221.Google Scholar
Ayd, F. J. (1956) Fatal hyperpyrexia following chlorpromazine therapy. Journal of Clinical and Experimental Psychopathology, 17, 189–192.Google Scholar
Baastrup, P. G., Hollnagel, P. & Sorenson, R. (1976) Adverse reactions in treatment with lithium carbonate and haloperidol. Journal of American Medical Association, 236, 2645–2646.Google Scholar
Barbelby, A. A. & Loepfe-Hinnkkaanen, M. (1979) Phenothiazines In Body Temperature, Regulation and Drug Effects and Therapeutic Implication (eds. Lomax, P. & Schonbaum, E.). New York: Marcel Dekker.Google Scholar
Billing, C. & Freeman, W. T. (1943) Fatal catatonia. American Journal of Psychiatry, 100, 633–638.Google Scholar
Boles, J. M., Lecam, B., Mialon, P., Pennec, Y. & Garre, M. (1982) Hyperthermie maligne des neuroleptiques. Guérison rapide par le dantrolene. La Nouvelle Presse Medicale, 11, 674.Google ScholarPubMed
Burke, R. E., Fahn, S., Mayeux, R., Weinberg, H., Louis, K. & Willner, J. (1981) Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology, 31, 1022–1026.CrossRefGoogle Scholar
Caroff, S. N. (1980) The neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 41, 79–83.Google Scholar
Caroff, S. N., Rosenberg, H. & Gerber, J. C. (1983) Neuroleptic malignant syndrome and malignant hyperthermia. Lancet, i, 244.Google Scholar
Chai, C. Y., Fann, Y. D. & Linn, M. J. (1976) Hypothermic action of chlorpromazine in monkeys. British Journal of Pharmacology, 57, 43–49.CrossRefGoogle ScholarPubMed
Clough, C. G. (1983) Neuroleptic malignant syndrome. British Medical Journal, 287, ii, 128–129.Google Scholar
Coons, D. J., Hillman, F. J. & Marshall, R. W. (1982) Treatment of neuroleptic malignant syndrome with dantrolene sodium–a case report. American Journal of Psychiatry, 139, 944–945.Google ScholarPubMed
Cope, R. V. & Gregg, E. M. (1983) Neuroleptic malignant syndrome. British Medical Journal, 286, i, 1938.Google Scholar
Delacour, J. C., Davodal, P., Chapoutot, J. L. & Tocq, B. (1981) Traitment du syndrome malin des neuroleptiques par le dantrolene. La Nouvelle Presse Medicale, 10, 3572–3573.Google Scholar
Delay, J., Pichot, P. & Lemperiere, T. (1969) Un neuroleptique majeur non phenothiazinique et non reserpinique, l'haloperidol dans le traitment des psychosis. Annals of Medical Psychology, 118, 145–152.Google Scholar
Delay, J. & Deniker, P. (1968) Drug induced extrapyramidal syndromes In Handbook of Clinical Neurology. Vol. 6. Diseases of the Basal Ganglia (eds. Vinken, D. & Bruyn, G.). Elsevier: New York.Google Scholar
Denborough, M. A., Collins, S. P. & Hopkinson, F. C. (1984) Rhabdomyolysis and malignant hyperpyrexia. British Medical Journal, i, 1878.Google Scholar
Exton Smith, A. N. (1972) Phenothiazines in cold weather. British Medical Journal, i, 441.Google Scholar
Gelenberg, A. J. (1967) The Catatonic syndrome. Lancet, i, 1339–1341.Google Scholar
Gelenberg, A. J. & Mandel, N. R. (1977) Catatonic reactions to high-potency neuroleptic drugs. Archives of General Psychiatry, 34, 947–950.CrossRefGoogle ScholarPubMed
Goekopp, J. G. & Carbaat, P. A. (1982) Treatment of neuroleptic malignant syndrome with dantrolene. Lancet, ii, 49–50.Google Scholar
Goulon, M., Rohan-Chabot, P., Elkharrat, D., Gajdos, P., Bismith, G. & Conso, F. (1983) Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome. a report of two cases. Neurology, 33, 516–518.Google Scholar
Granato, J. E., Stern, B. J., Ringel, A., Karim, A. H., Kromholtz, A., Coyle, J. & Adler, S. (1983) Neuroleptic malignant syndrome: successful treatment with dantroline and bromocryptine. Annals of Neurology, 14, 89–90.Google Scholar
Greenblatt, D. J., Gross, P. L., Harris, J., Shader, R. I., & Cirualo, D. A. (1978) Fatal hyperthermia following haloperidol therapy of sedative hypnotic withdrawal. Journal of Clinical Psychiatry, 39, 673–675.Google Scholar
Gronert, G. A. (1980) Malignant hyperthermia. Anaesthesiology, 53, 395–423.Google Scholar
Haberman, M. L. (1978) Malignant hyperthermia: an allergic reaction to thioridazine therapy. Archives of Internal Medicine, 138, 800–801.Google Scholar
Hoagland, R. J. & Bishop, R. H. (1961) a physiologic treatment of heat stroke. American Journal of Medical Science, 241, 415–244.CrossRefGoogle ScholarPubMed
Hofmann, R. A. & Zarrow, M. (1958) Hypothermia in the rat, hamster, ground squirrel and pigeon following chlorpromazine. American Journal of Physiology, 193, 547–552.Google Scholar
Itoh, H., Ohtsuka, N., Ogita, K., Yagi, G., Miura, S. & Koga, Y. (1977) Malignant neuroleptic syndroine. Its present status in Japan and clinical problems. Folia Psychiatrica et Neurologica Japonica, 31, 565–576.Google Scholar
Lancet (1984) Neuroleptic malignant syndrome. (Editorial.) Lancet, i, 545–546.Google Scholar
McCarron, M. M., Biettger, M. & Peck, J. J. (1982) a case of neuroleptic malignant syndrome successfully treated with amantadine. Journal of Clinical Psychiatry, 43, 381–382.Google Scholar
Marsden, C. D. & Jenner, P. (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychological Medicine, 10, 55–72.Google Scholar
May, D. C., Mooris, S. W., Stewart, R. M., Fenton, B. J. & Gaffney, F. A. (1983) Neuroleptic malignant syndrome. Annals of Internal Medicine, 98, 183–184.Google Scholar
Morris, H. H., Mccormick, W. F. & Reinarz, J. (1980) Neuroleptic malignant syndrome. Archives of Neurology, 37, 462–463.Google Scholar
Mueller, P. S., Vester, J. W. & Fermoglich, J. (1983) Neuroleptic malignant syndrome: successful treatment with bromocryptine. Journal of American Medical Association, 249, 386–388.CrossRefGoogle Scholar
Preston, J. (1959) Central nervous system reactions to small doses of tranquillisers. American Practice and Digest of Treatment, 10, 627–630.Google Scholar
Regestein, G., Alpert, J. & Reich, P. (1977) Sudden catatonic stupor with disastrous outcome. Journal of American Medical Association, 238, 618–620.Google Scholar
Rewerski, W. J. & Jori, A. (1968) Microinjection of chloropromazine in different parts of rat brain. International Journal of Neuropharmacology, 7, 359–364.CrossRefGoogle Scholar
Samii, K., Bagnat, E., Glaser, P., Nollet, D. & Simoni, G. (1976) Syndrome malin des neuroleptiques avec anuri d'évolution favorable. La Nouvelle Presse Medicale, 5, 1938.Google Scholar
Shields, W. D. & Bray, F. P. (1976) A danger of haloperidol therapy in children. Journal of Paediatrics, 88, 301–303.Google Scholar
Simpson, D. M. & Davis, G. C. (1984) Case report of neuroleptic malignant syndrome associated with withdrawal of amantadine. American Journal of Psychiatry, 141, 6, 796–797.Google Scholar
Singh, G. (1981) The malignant neuroleptic syndrome. Indian Journal of Psychiatry, 23, 179–183.Google ScholarPubMed
Smego, R. A. & Durack, D. T. (1982) The neuroleptic malignant syndrome. Archives of Internal Medicine, 142, 1183–1185.Google Scholar
Stauder, K. H. (1934) Die todliche Katatonie. Archiv für Psychiatrie und Nervenkrankheiten, 102, 614–634.Google Scholar
Szabadi, E. (1984) Neuroleptic malignant syndrome (Editorial). British Medical Journal, 288, 1399–1400.Google Scholar
Toru, M., Matsuda, O, Makiguchi, K. & Sugano, K. (1977) Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. Journal of Nervous and Mental Diseases, 169, 324–327.Google Scholar
Zelman, S. & Guillan, K. (1970) Heat-stroke in phenothiazine treated patients. A report of 3 fatalities. American Journal of Psychiatry, 126, 1787–1790.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.